newsfilter
← Latest News
GlobeNewswire·

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 DUBLIN, Ireland, and Boston MA, June 8, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company d